Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans. 28 May Dr D Modulation of the endocannabinoid system: neuroprotection or neurotoxicity? Targeting CB2 receptors and the endocannabinoid system for the treatment of pain